By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists agree that the choice between IYH and BBH involves complex trade-offs beyond simple risk-return dynamics. They highlight concentration risk, regulatory arbitrage, and liquidity concerns as key factors to consider, ultimately maintaining a neutral stance.
Risk: Concentration risk and regulatory headwinds
Opportunity: Potential for high returns in BBH given its exposure to biotech growth, despite the risks
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Investors choosing between iShares U.S. Healthcare ETF (NYSEMKT:IYH) and VanEck Biotech ETF (NASDAQ:BBH) may weigh the broader, lower-volatility healthcare exposure of IYH against the concentrated, high-growth biotechnology focus of BBH.
Investors choosing between the biotechnology subsector and the broader healthcare industry often weigh high growth potential against portfolio stability. While BBH focuses on 25 biotech firms, IYH includes 100 companies, like pharmaceutical giants and equipment makers. This comparison examines how these different strategies impact costs, risks, and yields.
| Metric | BBH | IYH | |---|---|---| | Issuer | VanEck | iShares | | Share price | $209.28 (as of 2026-07-08) | $68.56 (as of 2026-07-08) | | Expense ratio | 0.35% | 0.38% | | 1-yr return (as of 2026-07-08) | 33.60% | 22.80% | | Dividend yield | 0.50% | 1.20% | | Beta | 0.68 | 0.57 | | AUM | $411.4 million | $3.2 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
BBH is slightly more affordable with a 0.35% expense ratio compared to 0.38% for IYH. However, IYH provides a more significant payout, offering a 1.20% dividend yield compared to 0.50% for the biotech-focused fund.
| Metric | BBH | IYH | |---|---|---| | Max drawdown (5 yr) | (39.90%) | (17.90%) | | Growth of $1,000 over 5 years (total return) | $1,071 | $1,306 |
The iShares U.S. Healthcare ETF (IYH) provides broad exposure across the healthcare sector, which accounts for 100.00% of its portfolio. Its largest positions include Eli Lilly (NYSE:LLY) at 15.96%, Johnson & Johnson (NYSE:JNJ) at 10.42%, and Abbvie Inc (NYSE:ABBV) at 7.30% among its 100 total holdings. The fund was launched in 2000. iShares U.S. Healthcare ETF has paid $0.80 per share over the trailing 12 months, which, at its recent ~$68.56 share price, yields 1.20%.
The VanEck Biotech ETF (BBH) focuses on 25 companies involved in genetic research and diagnostics, with 100.00% of its portfolio allocated to the healthcare sector. Top holdings include Amgen Inc (NASDAQ:AMGN) at 14.84%, Gilead Sciences Inc (NASDAQ:GILD) at 13.21%, and Vertex Pharmaceuticals Inc (NASDAQ:VRTX) at 9.16%. The fund was launched in 2011. VanEck Biotech ETF has paid $0.96 per share over the trailing 12 months, which, at its recent ~$209.28 share price, yields 0.50%.
For more guidance on ETF investing, check out the full guide at this link.
The iShares U.S. Healthcare ETF (IYH) and the VanEck Biotech ETF (BBH) are both healthcare-focused exchange-traded funds (ETFs). Here's how they compare to one another.
Four leading AI models discuss this article
"Both ETFs are currently masquerading as sector diversification tools while actually functioning as highly concentrated bets on a handful of pharmaceutical giants and their specific drug pipelines."
The article presents a classic growth-versus-stability trade-off, but it misses the elephant in the room: concentration risk. IYH is essentially a proxy for the GLP-1 obesity drug trade, with Eli Lilly and AbbVie driving massive weightings. While IYH offers better risk-adjusted returns over five years, its current valuation is tethered to the sustainability of these high-margin drug franchises. Conversely, BBH’s 39.9% drawdown profile highlights the brutal reality of clinical trial binary outcomes. Investors shouldn't view these as simple sector bets; they are tactical plays on either defensive cash flow (IYH) or high-beta M&A cycles (BBH). I am neutral because both are currently trading at valuations that leave little room for clinical or regulatory disappointment.
The case against my neutrality is that the aging demographic tailwind is so powerful that both ETFs will likely outperform the broader market regardless of valuation, making the 'expensive' entry point irrelevant for long-term holders.
"N/A"
[Unavailable]
"BBH's superior 1-yr return masks 2.2x worse downside risk and liquidity constraints, making IYH the better fit for most investors unless biotech innovation accelerates materially."
The article frames this as a straightforward risk-return tradeoff, but the data tells a more complex story. BBH's 33.6% 1-yr return versus IYH's 22.8% looks impressive until you see BBH's 39.9% max drawdown versus IYH's 17.9%—that's 2.2x worse downside. More troubling: BBH's beta of 0.68 contradicts its drawdown severity; five-year monthly returns don't capture recent volatility spikes in biotech. The $411M AUM in BBH also raises liquidity concerns during stress. IYH's 1.2% yield plus lower drawdown suggests better risk-adjusted returns, yet the article never calculates Sharpe ratio or discusses sector rotation timing.
BBH's outperformance could persist if biotech innovation cycles accelerate and large-cap pharma (LLY, JNJ, ABBV) face patent cliffs—in which case the concentrated bet wins despite higher volatility. The article's 5-year window may be stale if biotech tailwinds are just beginning.
"Concentrated biotech exposure in BBH can deliver outsized upside in favorable regulatory cycles, so investors shouldn't dismiss BBH solely on higher drawdowns."
The piece frames IYH as steadier and BBH as turbocharged biotech, but it glosses risk items that matter for a real-world decision. BBH’s 25 holdings concentrate risk on a handful of names whose fortunes hinge on FDA timing, trial results, and reimbursement; a string of disappointing reads can trigger sharp drawdowns even if long-run growth looks compelling. IYH’s broad 100-holdings mix includes pharma giants that may lag biotech surges but provide ballast through dividends and more predictable cash flows. The article uses trailing yields and five-year drawdowns to imply safety; it ignores regime risk, potential policy swings, and liquidity dynamics that disproportionately hit high-growth biotechs.
The concentrated BBH basket offers outsized upside when a few biotech breakthroughs clear, which could dwarf IYH’s diversification; ignoring this optionality yields an incomplete risk/reward read.
"The valuation of biotech ETFs like BBH is currently more sensitive to antitrust regulatory risk than to the success of individual clinical trials."
Claude, your focus on BBH's liquidity is valid, but you’re missing the regulatory arbitrage. The real risk isn't just clinical trial failure; it's the FTC’s aggressive stance on pharma M&A. If the DOJ continues to block mid-cap acquisitions, the 'exit strategy' for BBH’s holdings evaporates, stripping away the sector's primary valuation floor. We aren't just betting on science; we are betting on whether the government allows the industry’s natural consolidation cycle to function.
[Unavailable]
"FTC M&A restrictions redistribute returns between biotech and large-cap pharma rather than destroying value uniformly."
Gemini's FTC arbitrage angle is sharp, but it conflates two separate risks. M&A blockage hurts *exit multiples* for BBH holdings—true. But it doesn't eliminate the underlying biotech thesis; it just extends hold periods and shifts returns from acquirers to public equity holders. Conversely, IYH's pharma giants *benefit* from reduced M&A competition, which actually tightens their moats. The regulatory headwind is real, but it's not uniformly bearish across both ETFs.
"Regulatory M&A delays are real but BBH's upside rests more on pipeline breakthroughs and pricing dynamics than on deal exits, so antitrust blocks alone won't derail the thesis."
Gemini’s FTC arbitrage angle overstates the risk: even if antitrust blocks slow consolidation, BBH’s upside isn’t contingent on mid-cap takeovers alone; value accrues from trials, partnerships, and licensing that can re-rate names without deal exits. The bigger risks are pipeline failures and policy-driven pricing/regulatory shifts. Do scenario analysis across trial outcomes, FDA timing, and public-market re-ratings, not just exit multiples. That keeps BBH enterable, but valuations hinge on durable pipelines and credible reimbursement.
The panelists agree that the choice between IYH and BBH involves complex trade-offs beyond simple risk-return dynamics. They highlight concentration risk, regulatory arbitrage, and liquidity concerns as key factors to consider, ultimately maintaining a neutral stance.
Potential for high returns in BBH given its exposure to biotech growth, despite the risks
Concentration risk and regulatory headwinds